← Leaderboards
Glenn W Laub
Tdl Innovations, Llc
$1,269,300
Attributed
$2,314,083
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $959.7K · FY2017–21$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,314,083 · 3
By mechanism
R44$1,890,220 · 1
R43$224,516 · 1
SB1$199,347 · 1
Top collaborators
- Richard Brian Huneke2 shared
- James A Wilkie1 shared
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsPropertyFormulationPalliativePleurodesisPropellantDrainage ProcedureFailureMalignant NeoplasmsOryctolagus CuniculusPleural CavityBiomaterial CompatibilityPreventProceduresCancer PatientComplicationAnimal ModelEffectivenessLiquid SubstanceLungMalignant Pleural EffusionMinimally InvasiveAffectQuality Of Life
Grant awards (4)
An Improved Method of Delivering a Sclerosing Agent for the Treatment of a Malignant Pleural Effusion.$199,347
SB1 · FY2021 · CA · contact PI
An Improved Method of Delivering a Sclerosing Agent for the Treatment of a Malignant Pleural Effusion.$959,737
R44 · FY2020 · CA · contact PI
An Improved Method of Delivering a Sclerosing Agent for the Treatment of a Malignant Pleural Effusion.$930,483
R44 · FY2019 · CA · contact PI
An Improved Method of Delivering a Sclerosing Agent for the Treatment of a Malignant Pleural Effusion$224,516
R43 · FY2017 · CA · contact PI